drugset
drugset / Trial / NCT05599191

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05599191 ↗

Phase 3 Completed 957 enrolled Bellus Health Inc. - a GSK company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Timeline

Start
2022-10-25
Primary completion
2025-12-17
Completion
2026-06-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Camlipixant Small molecule 25 mg Oral
Subject Camlipixant Small molecule 50 mg Oral

Indications

respiratory system disorder